advanced colorectal cancer recieving moterate emetic chemotherapy
Conditions
Interventions
palonosetoron and dexamethasone
Sponsors
Osaka City General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age; more than 20 years-old 2. Histologicaly proven colorectal cancer 3. Chemotherapy naive 4. Patients recieving moderate emetic chemorerapy including oxaliplatin or irinotecan 5. Adequate organ function as follows: WBC > 3000/mm3, AST < 100IU/L, ALT < 100IU/L 6. Perfomance Status(ECOG): 0-2 7. Written informed consent
Exclusion criteria
Exclusion criteria: 1. Uncontrolled severe complication disease, such as ileus, idiopatic pulmomary fibrosis, daibetes, cardiac infarction, angina pectoris, renal failure, hepatic failure, mental disorder, cerebral vansular disease, active gastrointestinal tract ulcer. 2. Symptomatic brain metastasis 3. Epilepsy patint treated with antiepileptic agent, exclusing being stable clinically 4. Patient with massive pleural effusion or ascitis to be required dranage 5. Obstruction of the gastric outlet or ileus 6.Grade 2 or more nausea and vomiting 7.Anaphylaxis to palonosetron or dexamethasone 8. Patients treated with 5-HT3 antagonist, NK1 antagonist, SSRI, SNRI 9.Patient not to use birth contorol 10. Unsuitable patients by investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MAT(MASCC Antiemesis Tool) QOL-ACD(The QOL Questionnaire for Cancer Patients Treated with Anticancer Drugs) | — |
Secondary
| Measure | Time frame |
|---|---|
| safety | — |
Countries
Japan
Contacts
Public ContactKoji Takeda
Osaka City General Hospital Department of Clinical Oncology
Outcome results
None listed